Metastatic CRC after failure of treatment w/ fluoropyrimidines as monochemotherapy or w/ fluoropyrimidines. In combination w/ 5-fluorouracil (5-FU) & folinic acid for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor; metastatic CRC.
IV infusionAdultRecommended dose as single agent: 130 mg/m2 over at least 2 hr every 3-4 wk. In combination w/ 5-FU, w/ or w/o folinic acid: 130 mg/m2 every 3 wk or 85 mg/m2 every 2 wk. Adjuvant setting 85 mg/m2 repeated every 2 wk for 12 cycles (6 mth). Metastatic CRC 85 mg/m2 repeated every 2 wk. In combination w/ capecitabine: 130 mg/m2 repeated every 3 wk.
View Oxitan overdosage for action to be taken in the event of an overdose.
Contraindications
History of hypersensitivity. Myelosuppression prior to starting 1st course (baseline neutrophils <2 x 109/L &/or platelet count of <100 x 109/L). Peripheral sensitive neuropathy w/ functional impairment prior to 1st course. Severe renal impairment (CrCl <30 mL/min). Lactation.
Hypersensitivity reactions including anaphylaxis. Not to be given in patients w/ preexisting sensory neuropathies or myelosuppression. Perform neurological exam at regular intervals during treatment & reduce dose if symptoms are prolonged or severe; regular blood counts during treatment. Monitor renal function & toxicity in patients w/ more moderate degrees of renal impairment. Not to be given in severe renal impairment. Severe hepatic impairment. Use appropriate contraceptive measures during & for 6 mth after stopping treatment for men & for 4 mth for women. Not recommended during pregnancy. Contraindicated in lactation. Childn.
Sign Out
